Ventripoint Receives CE Mark for VMS+ Whole Heart Analysis System

Toronto, Ontario, January 8, 2018 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT) is pleased to announce that it has received the European CE Mark for the VMS+ Whole Heart Analysis System, which allows the Company to begin selling the VMS+ throughout the European Union. This system uses conventional 2D ultrasound to analyse all four chambers of the heart in minutes with accuracy equivalent to MRI.

"This is great news as it allows the Company to bring the capabilities of the VMS+ to cardiologists in Europe and improve cardiac care," stated Dr. George Adams, CEO of Ventripoint. "The quick acceptance of the VMS+ application is a credit to our development and regulatory groups."

According to the European Heart Network, cardiovascular disease (CVD) causes 3.9 million deaths in Europe annually and accounts for 45% of all deaths in Europe. In 2015, there were just under 11.3 million new cases of CVD in Europe and more than 85 million people in Europe were living with CVD. Overall CVD is estimated to cost the European economy €210 billion ($300B) a year.

The CE Mark is also recognized worldwide and will allow the Company to register the VMS+ in many additional regions and countries. This will greatly expand the commercial opportunities and allow distributors to sell into their regions.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information, please contact:
Dr. George Adams, CEO
telephone: (519) 803-6937
email: gadams@ventripoint.ca

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address

Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.